Furthermore, a significant correlation between the MUC16 mutation with tumour mutational burden and microsatellite status was shown in patients with gastric cancer (Zhang et al., 2022), colorectal cancer (Wang et al., 2020), and melanoma (Zhang et al., 2020; Wang et al., 2022b) which signifies the used of immune checkpoint inhibitor (ICI) in the treatment regimen. This evidence concerns the gene MUC16 and melanoma.